Investor
Ideas #Potcasts 610, #Cannabis News and #Stocks on the Move: (CSE: $AUSA.C)
(OTC: $AUSAF) (TSXV: $KHRN.V) (CSE: $XBRA.C) (CSE: $DELC.C)
Delta, Kelowna, BC, November 3, 2021 (Investorideas.com
Newswire) www.Investoride, as.com, a global news source covering leading sectors
including marijuana and hemp stocks and its potcast site, www.potcasts.ca release today’s podcast edition of cannabis news and stocks to watch plus insight
from thought leaders and experts.
Listen to the podcast:
https://www.investorideas.com/Audio/Podcasts/2021/110321-StocksToWatch.mp3
Read this in full
at https://www.investorideas.com/news/2021/cannabis-potcasts/11031AUSA-KHRN-XBRA-DELC.asp
Hear Investor ideas cannabis potcast on iTunes
Hear the investor ideas potcast on Spotify
Today’s podcast overview/transcript:
Good
afternoon and welcome to another episode of Investorideas.com
"Potcast" featuring cannabis news, stocks to watch as well as
insights from thought leaders and experts.
In today’s podcast
we look at a few public company announcements.
Terry Booth, CEO, of AUDACIOUS (CSE: AUSA) (OTC: AUSAF) announced that the Company has entered into a
term sheet in regards to the formation of a strategic partnership with Golden
Triangle Health (GTH), a subsidiary of NR Instant Produce PCL ("NRF"),
a leading southeast Asian food manufacturer and distributor based in Thailand,
producing its own signature brands private label products and co-packaging
lines.
Terry Booth, CEO, said, "This
is an Audacious partnership whereby we will take our know-how and IP and help
our partner optimize operations, product development and utilize our joint
marketing and influencer networks to establish a leader in the rapidly growing
Asian CBD market. Tom, who we know firsthand as an exceptional business
executive with a strong track record in execution, and his team have built an
amazing company already. We had been in talks for some time, but everything
accelerated due to our presence at MJBizCon, which enabled us to meet face to
face and execute on what we believe will be an exceptional opportunity to
establish the AUDACIOUS brand internationally. We are very proud of this
partnership that makes us, to the best of our knowledge, the first
international company with an operational presence in the Asian legal cannabis
market."
Mr. Booth added "We believe in
the many benefits of CBD and we have the science to prove it. Our discussions
with GTH have been diligent and the entire group is aligned with a strong
strategy going forward. Tom is a charismatic man with tonnes of positive energy
and a force to be reckoned with in Southeast Asia. AUDACIOUS look forward to
building our relationship with GTH and their partners globally."
Tom Kruesopon, Director of GTH,
added, "While we have strong brand equity in Thailand and large parts of
Asia already, combining with AUDACIOUS will lift our recognition to the next
level. The combined know-how and our existing partnerships form a very solid
foundation to build what we believe can be one of the most meaningful players
in the Asian CBD market. I look forward to working closely with Terry and the
amazing team at AUDACIOUS and bringing our existing and new product lines to
the Asian markets and likely beyond."
Strategic
Rationale
● The Thai
market for CBD products is in its infancy, as GTH projects the market to reach
approximately $1 billion in Thailand at maturity.
● Hemp was
authorized as legal in January 2021, and a limited number of licenses were
granted by the authorities to date, providing early mover advantage to GTH
● Provides
AUDACIOUS with a well-established partner in a CBD derived from hemp market,
poised for rapid growth
● Positions
AUDACIOUS for further international expansion
● Provides
an early mover advantage due to the limited number of licenses granted to date
● Well
aligned with the AUDACIOUS strategy for capital light expansion, as under the
deal terms, AUDACIOUS is not required to provide capital for construction,
working capital or other purposes
● Through
GTH's parent company, the partnership will have access to large, well-established
distribution networks throughout Thailand, Asia and North America
● GTH is
authorized to distribute products through e-commerce and B2C networks
● Partnership
will benefit from being the exclusive distribution partner for Cookies in Asia
(excluding Japan). Cookies is the iconic California brand, founded by Berner,
one of the most respected entrepreneurs in the cannabis space, among others due
to their attention to high-quality genetics.
● GTH has
access to a broad portfolio of infused and non-infused (industrial hemp)
products, diversifying revenue streams
● GTH
provides AUDACIOUS with the ability to leverage its network of Asian
influencers to expand brand and company recognition in this market
The partnership
The
purpose of the partnership is to develop GTH into the most meaningful CBD
player in the Asian market. AUDACIOUS will provide advisory services,
operational intelligence, including cultivation, manufacturing, and product
development, and expansion of brand visibility in Thailand and beyond. Further,
the potential exists for AUDACIOUS to become an export partner for GTH's Thai
product portfolio, to include CBD and Hemp consumables, topicals and other hemp
derived commodities. Products will be sold under the GTH brand, as well as through
B2B channels under white label agreements.
Under
the terms of the agreement, AUDACIOUS and GTH will enter into a share swap in
two tranches whereby a total of up to $4 million in shares will be exchanged,
contingent upon GTH reaching certain milestones. Each tranche is of equal size
(US$2 million), with the second tranche payable only upon GTH achieving
profitable operations. Upon completion, AUDACIOUS will obtain an ownership
interest of up to 25% in GTH, as well as three board seats.
Khiron Life Sciences
Corp.
(TSXV: KHRN) (OTCQX: KHRNF), a vertically integrated medical
cannabis leader with core operations in Latin America and Europe, announced the opening of Zerenia™ Clinics UK
in London as its first International Zerenia™ clinic in Europe. This
collectively brings the Company's total clinic count to 15 globally. Both
virtual and in-person appointments can be made via the website www.zereniaclinic.co.uk.
Khiron in the
United Kingdom
The
company is pursuing a consistent approach to improve patient access to medical
cannabis and to develop the market for medical cannabis treatments in the UK.
The opening of Zerenia™ Clinics UK by an expert team is another step in this
direction that expands Khiron's presence in Europe, where medical cannabis
sales have grown more than 6x since Q1 2021. Even though Germany will continue
to dominate the European market for medical cannabis until at least 2024,
industry consultants Prohibition Partners expect the UK medical cannabis market
to show the most significant growth of any country in Europe by 2025.
Zerenia™
Clinics UK will build upon Khiron's presence in the UK which started in 2019
when Khiron became a founding member and also the exclusive Latin American
supplier for Project Twenty21 which offers a subsidized pricing model for
patients in the program to help address barriers to access in the UK market.
The Company continues to focus on medical training for healthcare professionals
after receiving full Continuing Professional Development ("CPD")
accreditation for its digital educational platform, Khiron Academy, and brings
its proprietary clinical data generated in LatAm to the UK.
The Zerenia™ Clinic
model
In
the initial phase of operations, Zerenia™ Clinics UK will focus on pain
management and will then expand its therapeutic portfolio to other areas such
as mental health, women´s health, neurology and oncology. Though prominently
located in London's famous Chelsea district, Zerenia™ Clinics UK will initially
focus on supporting patients digitally (or via video-consultations) to enable
streamlined access to patients across the UK, many of whom suffer from
debilitating conditions. Zerenia™ Clinics UK follows the high-quality standards
of personalised cannabinoid-based therapies and pursues precision-based
medicine with the central goal to improve patient access to cannabinoid-based
therapies.
In
LatAm, the proven clinic model Zerenia™ is a patient-centered integrated care
model combining traditional and complementary medicine with a focus on
treatments with medical cannabis. The 14 Zerenia™ clinics in Colombia and Peru
are known for their evidence-based treatments and highly professional
applications with over 14,000 individual patients treated to date.
Franziska
Katterbach, President Khiron Europe commented, "I am very excited about
the opening of Zerenia™ Clinics UK in London with our very experienced local
team. This is a great milestone for Khiron and will contribute significantly to
the dynamics of developing a market for medical cannabis in the UK. From day
one, it has been our goal to improve patient access to medical cannabis where
suitable and also create evidence for the effectiveness and tolerability of
medical cannabis; opening a UK cannabis clinic is just another logical step to
serve patient's and clinician's needs."
Xebra Brands Ltd. (CSE: XBRA), a cannabis company, announced that it has commenced its pre-trial
cultivation of cannabis in the Netherlands.
As
1 of only 5 companies to be selected by the Dutch government to participate in
trial medicinal cannabis cultivation, Xebra is endeavoring to be awarded 1 of 2
licenses, with a contract for up to 6 years, providing for revenues of up to
€70.5 million, to co-supply all pharma-grade cannabis to be sold in the
Netherlands.
Cultivation
in the Netherlands is conducted in Xebra's indoor facility. Xebra's specific
genetic varieties are characterized by high production, compact flowers of
excellent quality and fine tasting terpene profiles, with a growth cycle of
12-16 weeks.
Rodrigo Gallardo,
President of Xebra, commented, "We are pleased to have commissioned our facility ahead of schedule,
allowing us to conduct a pre-trial cultivation crop cycle, prior to
commencement of the formal trial in December."
Delic
Holdings Corp (CSE: DELC) (OTC: DELCF), a leader in new medicines and
treatments for a modern world, released the full entertainment lineup for
Meet Delic, the two-day premier psychedelics event on November 6th and 7th.
From pop-royalty dance performers and groundbreaking visual experiences to new
technologies and research, thought-provoking presentations, and the world's
largest psychedelic business expo, there will be something for everyone to
explore.
Meet Delic is the largest and most
comprehensive event to learn about the intersection of psychedelics, wellness,
and business with like-minded visionaries. The entertainment lineup spans the
worlds of music, visual technology, and performance art and will be joining
headliners Lamar Odom, Duncan Trussell, Alyson Charles, Ifetayo Harvey, Dr.
Carl Hart, George Goldsmith, Ekaterina Malievskaia, M.D., Zappy Zapolin, Aubrey
Marcus and many more for an unforgettable experience:
Little
Miss Nasty, November 6 and 7: Beyoncé, Justin Bieber, Ariana Grande,
Britney Spears, Usher, Katy Perry, Nick Jonas and Lady Gaga. These superstars
are only some of the artists on this high-energy dance duo's impressive resume.
What started as a "rock and roll burlesque" dance show in Los Angeles
has evolved into a performance art group and lifestyle brand with global tours
and multiple sold-out residencies in Las Vegas, Long Beach and San Francisco.
Sporeganic,
November 6 and 7: Scott Hedstrom, whose pseudonym is Sporeganic, has
created spectacular live visual experiences at shows for artists such as The
Grateful Dead side project Billy & The Kids, STS9, Android Jones and
CloZee. As the Technical Director at Vision Agency, he and his team created the
psychedelic visuals tool, Microdose VR, which brings audiences on cinematic
journeys through psychedelic landscapes. Hedstrom is focused on building the
technology behind the upcoming biofeedback VR experience, Chromadose.
DJ
David Starfire & Live VJ Jonathan Singer, November 6: This
duo will celebrate the legends of psychedelia through a journey of sight and
sound during a live tribute featuring the music of The Grateful Dead, The
Beatles, Pink Floyd, Jefferson Airplane and Jimi Hendrix. A special live,
immersive 360 visual performance set to Pink Floyd's "Set The Controls For
The Heart Of The Sun" and Futuristic Psychedelia Dance and Techno themes
featuring the music of Tipper, Desert Dwellers and David Starfire will close
out the set.
Mindchatter,
November 7:
New York City-based singer, songwriter and producer Bryce Connolly, who goes by
Mindchatter, is known for creating sounds that defy genre and writing lyrics
tinged with introspection. His first single "Trippy'' was released in
2019, growing his avid fan base and garnering praise from BBC Radio 1's
renowned DJ, Pete Tong. In 2020 Mindchatter debuted his first album, Imaginary Audience, and kicked off his
own slate of headlining shows that combine his ethereal beats with
one-of-a-kind visual experiences.
Meet Delic is committed to bringing
awareness of the science-backed benefits of psychedelics and business
opportunities to the mainstream and larger global community by reframing the
psychedelic conversation. The twenty hours of panels and keynotes will include
an array of topics such as Accelerating
Adaptation: What Psychedelic States can teach us about Healing, Aphrodisiacs
and Psychedelics: A History of Medicine for Love, Fentanyl in our Drugs,
Ketamine: An Intimate Discussion on the New Wonder Drug for PTSD, Deciphering the Medical Potential of
Psychedelics, A Discussion with George Goldsmith & Ekaterina Malievskaia
featuring Clara Burtenshaw, Psychedelics and Futurism.
Tickets are now available for the two-day experience. For
more information please visit, meetdelic.com.
Finally, in a recent news article
from MJBiz Daily, “banking giant JPMorgan Chase & Co. informed its
brokerage clients they’ll no longer be allowed to purchase cannabis-related
stocks and securities starting Nov. 8.”
Reuters on Tuesday cited an internal JPMorgan
letter to brokers that said, in part, “J.P. Morgan (JPMS) has introduced a
framework that is designed to comply with U.S. money laundering laws and
regulations by restricting certain activities in the securities of U.S.
Marijuana Related Businesses.”
The
New York-based bank’s restriction applies to any company that has a “direct
nexus to marijuana-related activities,” even those that aren’t traded on major
exchanges such as the Nasdaq, New York Stock Exchange or Toronto Stock
Exchange.
After
Nov. 8, JPMorgan clients with positions in marijuana companies will be allowed
to liquidate their shares, according to the bank’s letter.
This
pivot by JPMorgan is similar to Credit Suisse Group, which told clients it was
calling off all transactions involving marijuana-related companies in the
United States earlier this year which reportedly led to a huge selloff of
cannabis stocks.
U.S.
Cannabis Council CEO Steve Hawkins called JPMorgan’s decision “beyond
disappointing.”
“JPMorgan’s
new policy is regressive and at odds with the majority of Americans, who want
legal, regulated cannabis. What’s more, it’s self-defeating,” Hawkins said in a
statement. “The end of federal cannabis prohibition is within sight, and the
industry is already growing rapidly. I imagine more than a few JPMorgan
customers will take issue with being blocked from one of the hottest industries
on the market today. JPMorgan is on the wrong side of history on this and will
come to regret its decision.”
Industry
CEOs also spoke out, such as Doug Chloupek, CEO, Juva Life (CSE:JUVA who commented, “This news is
disappointing, but not surprising. In the end, cannabis is still federally
illegal and most in the ancillary space ie. insurance, finance, brokers,
suppliers, real estate and regulators have used this to their advantage to
leverage high fees for typically lackluster services. This is just another blow
to the already burdened industry. You can mark it as yet another step backwards
in what is supposed to be forward progress. This move will limit the growth of
businesses who are working above board, already following a set of complex
rules, further pushing the cannabis industry underground and limiting
innovation as a whole.”
Blake
Schroeder, Esq, CEO of Medical
Marijuana, Inc. (OTC: MJNA) commented, "The longer we
prolong federal cannabis legislation, the more financial institutions we will
see making similar statements as JPMorgan. As the first-ever cannabis company
to become publicly traded in the US, as well as on OTC Markets, we've witnessed
the many ups and downs of cannabis stocks over the years and have been
pleasantly surprised that cannabis has been one of the few industries to come
out of the pandemic even stronger than before. We’ve seen positive movement for
the industry on both the federal level, with the passage of the 2018 Farm Bill,
and many state levels, including the recent passage of California AB 45. We
hope that financial institutions and regulators see clearly the positive
movement that is happening around the world and, instead of making decisions
like this that do more harm than help in keeping people safe from fraud,
positively align. We will continue to fight for fair access to financial
services for as long as it takes.”
Investor
ideas reminds all listeners to read our disclaimers and disclosures on the
Investorideas.com website and that this podcast is not an endorsement to buy
products or services or securities. Investors are reminded all investment
involves risk and possible loss of investment.
Learn
more about our cannabis podcasts at https://www.investorideas.com/Audio/Potcasts.asp
Or www.potcasts.ca
To hear
more Investorideas.com
podcasts visit: https://www.investorideas.com/Audio/.
The Investorideas.com
podcasts are also available on iTunes ( Apple Podcasts) , Audible , Spotify, Tunein, Stitcher,
Spreaker.com, iHeartRadio , Google
Podcasts and most audio platforms available.
Potcasts is now a certified
word mark Trademark on the blockchain through Cognate, Inc. CM
Certification-Registration Number: 10468217708
About Investorideas.com - News that
Inspires Big Investing Ideas
Investorideas.com
publishes breaking stock news, third
party stock research , guest posts and original
articles and podcasts in leading stock sectors. Learn about investing in stocks and get investor ideas in cannabis, crypto, AI and
IoT, mining, sports biotech, water, renewable energy, gaming and more. Investor
Idea’s original branded content includes podcasts and columns : Crypto
Corner , Play by Play sports and stock news , Investor Ideas Potcasts Cannabis News and Stocks on the Move podcast
, Cleantech and Climate Change , Exploring Mining , Betting on Gaming Stocks Podcast and the AI Eye
Podcast.
Disclaimer/Disclosure: Investorideas.com is a
digital publisher of third party sourced news, articles and equity research as
well as creates original content, including video, interviews and articles.
Original content created by investorideas is protected by copyright laws other
than syndication rights. Our site does not make recommendations for purchases
or sale of stocks, services or products. Nothing on our sites should be
construed as an offer or solicitation to buy or sell products or securities.
All investing involves risk and possible losses. This site is currently
compensated for news publication and distribution, social media and marketing,
content creation and more. Disclosure is posted for each compensated news
release, content published /created if required but otherwise the news was not
compensated for and was published for the sole interest of our readers and
followers. Contact management and IR of each company directly regarding
specific questions. More disclaimer info: https://www.investorideas.com/About/Disclaimer.asp Learn more about publishing your news release and our
other news services on the Investorideas.com newswire https://www.investorideas.com/News-Upload/ and tickertagstocknews.com
Global investors must adhere to regulations of each country.
Please read Investorideas.com privacy policy: https://www.investorideas.com/About/Private_Policy.asp
Investor Ideas does not condone the use of cannabis except where
permissible by law. Our site does not possess, distribute, or sell cannabis
products.
Learn more about sponsoring this podcast or be a guest
and our other branded content opportunities at Investorideas.com
Follow
us on Twitter https://twitter.com/Investorideas
Follow
us on Facebook https://www.facebook.com/Investorideas
Follow
us on YouTube https://www.youtube.com/c/Investorideas
Download
our Mobile App for iPhone and Android
Join our
Investor Club https://www.investorideas.com/membership/
Contact Investorideas.com
800 665
0411
Get more
Cannabis
Stock Investor Ideas – news, articles,
podcasts and stock directory
